1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

  • February 2014
  • 59 pages
  • GlobalData
Report ID: 2081701

Summary

Table of Contents

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Zicronapine is a D1, D2, and 5-HT2A receptor antagonist in development by Lundbeck. Zicronapine preferentially binds to D1 receptors over D2 and it has a unique affinity for other monoamine receptors, rendering a theoretical utility in psychosis, schizophrenia, and other conditions in which pro-cognitive agents may be useful.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Zicronapine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Zicronapine for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Zicronapine performance
- Obtain sales forecast for Zicronapine from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
Parkinson%s disease forecast and market analysis to 2035

Parkinson%s disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Sizable pipeline characterized by both high growth and attrition Parkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness ...

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

  • $ 4950
  • Industry report
  • April 2017
  • by Frost & Sullivan

Disease-Modifying Treatments Likely to Transform the Clinical Management of Alzheimer’s and Parkinson’s Diseases The research service primarily encompasses comprehensive analyses of key emerging therapies ...

Central Nervous System Disorder Drugs Markets in China

Central Nervous System Disorder Drugs Markets in China

  • $ 4000
  • Industry report
  • May 2017
  • by Asia Market Information & Development Company

China’s demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.